Highbridge Capital & Ayrmid offer $45M to buy bluebird bio, topping Carlyle/SK Capital's $29M bid, with additional payment ...

Lykos Therapeutics’ interim CEO Michael Mullette is planning to step down, according to a source familiar with the decision.

Appeals court upholds J&J win blocking Mylan's generic version of schizophrenia drug Invega Trinza, protecting patent for ...

Novartis’ prostate cancer radiopharmaceutical Pluvicto has netted a highly anticipated and highly delayed expanded indication ...

Alumis and Acelyrin had merger talks in 2023 before current deal. SEC filing shows earlier reverse merger attempt, followed ...

BioNTech's BNT327 shows promising survival data in lung cancer trial, with 72.7% of patients surviving one year, ...

FDA approves Sanofi's RNAi hemophilia drug fitusiran, licensed from Alnylam, to treat both hemophilia A and B by lowering ...

Eli Lilly’s Alzheimer’s drug Kisunla has failed to get support from the European Medicines Agency over serious side effects ...

CHMP backs label expansions for BMS's Opdivo, BeiGene's Tevimbra, AstraZeneca's Calquence & others; recommends approval of ...

DBV Technologies could get $306M for peanut allergy patch; Eisai sells Pariet rights in China; Palatin reports UC trial data; ...

Novo Nordisk partners with Lexicon Pharmaceuticals for obesity drug LX9851 in deal worth up to $1B, including $75M upfront ...

Merck KGaA pays $85M for global rights to Abbisko's pimicotinib, a CSF-1R inhibitor for TGCT that competes with Daiichi ...